new peptide retatrutide GLP-3 R 15mg 🎙️ NEW EPISODE: Retatrutide—The Triple

Further changes involving receptor affinity and activation occurred specifically in monotremes

New indications expand use cases Perhaps just as important as the wave of new GLP-1/GIP drugs for obesity is the expansion of already approved GLP-1 drugs into other therapeutic areas

You may be a good candidate for semaglutide if you are overweight or obese and at risk for weight-related conditions such as high blood pressure, type 2 diabetes, or high cholesterol

Readers should verify the current authorisation status via the MHRA and EMA medicines databases, as the regulatory position may change as Phase 3 data mature